RxDoctor Payments Data

Patience Terkowski

Nurse Practitioner · Pottstown, PANPI 1467707885

Payments from drug & device makers

$1,583in general payments, 2019–2025

Across 44 payments — averaging $35.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$314
  • Pfizer$226
  • Novartis$177
  • Johnson & Johnson$144
  • Seagen Inc.$135
  • AbbVie$105
  • plus $482 from 15 others

What the payments were for

  • Food & beverage$1,31983%
  • Education$26417%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,583 in reported general payments places this provider in the 85th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$46,310
Medicare patients
129
Services billed
394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib22$362,534
CalquenceAcalabrutinib Maleate12$184,233
InlytaAxitinib12$110,516
EliquisApixaban38$30,897
XareltoRivaroxaban34$29,401
Enoxaparin Sodium15$3,829
Anastrozole98$2,549
Oxycodone Hcl125$1,203
Morphine Sulfate20$806
Gabapentin26$782
Hydroxyurea35$717
Tamoxifen Citrate24$671
Acyclovir23$523
Lidocaine-PrilocaineLidocaine/Prilocaine38$438
Morphine Sulfate ErMorphine Sulfate14$371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$20$362,53422 claims
AstraZenecaCalquence$314$184,23312 claims
PfizerInlyta, Eliquis$226$141,41350 claims
Johnson & JohnsonXarelto$144$29,40134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Pottstown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →